Vincerx Pharma to merge with Oqory Inc., focusing on cancer treatment with promising results.

From GlobeNewswire: 2024-12-27 16:05:00

Vincerx Pharma, Inc. has announced a proposed merger with Oqory, Inc., a clinical-stage company developing ADCs for cancer treatment. Post-merger, Oqory equity holders will own 95% of the combined entity. Vincerx is also implementing cost-control measures and workforce reductions. Oqory’s anti-TROP2 ADC has shown positive results in clinical trials with no severe side effects reported. OQY-3258, Oqory’s lead ADC, is currently in Phase 3 trials for breast cancer treatment. The merger is subject to various closing conditions, including regulatory approvals and stockholder approval from both parties.



Read more at GlobeNewswire: Vincerx Pharma Enters into a Binding Term Sheet for a